Summit Therapeutics plc (SMMT) News
Filter SMMT News Items
SMMT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SMMT News From Around the Web
Below are the latest news stories about SUMMIT THERAPEUTICS INC that investors may wish to consider to help them evaluate SMMT as an investment opportunity.
Insiders hold 82% of Summit Therapeutics Inc. (NASDAQ:SMMT), and they've been buying recentlyKey Insights Insiders appear to have a vested interest in Summit Therapeutics' growth, as seen by their sizeable... |
Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call TranscriptSummit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, and welcome to the Summit Therapeutics Third Quarter 2023 Earnings and Update Call. All participants will be able to listen only until the question-and-answer portion of this call. We do not expect any technical difficulties today; however, in the event […] |
Summit Therapeutics Inc (SMMT) Reports Q3 Financial Results and Operational ProgressCompany's net loss for the nine months ended September 30, 2023, stands at $578.4 million, largely due to in-process research and development expenses |
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023MENLO PARK, Calif., November 07, 2023--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter and nine months ended September 30, 2023. |
Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical DevelopmentMENLO PARK, Calif., November 02, 2023--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development. |
Ivonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023MENLO PARK, Calif., October 31, 2023--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego, CA. The poster with updated data describing ivonescimab’s mechanism of action will be displayed on Saturday November 4, 2023, from 11:55am to 1:25pm Pacific Time. |
Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023MENLO PARK, Calif., October 26, 2023--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its third quarter 2023 financial results and provide an operational update for the Company on Tuesday, November 7, 2023, before the market opens. |
H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical DevelopmentMENLO PARK, Calif., October 19, 2023--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Howard "Jack" West, MD, has joined Summit Therapeutics as Vice President of Clinical Development focused on lung cancer. |
Insider Buying: COO Manmeet Soni Acquires 2,976,190 Shares of Summit Therapeutics IncIn a significant move, Manmeet Soni, the Chief Operating Officer (COO) of Summit Therapeutics Inc (NASDAQ:SMMT), purchased 2,976,190 shares of the company on October 13, 2023. |
Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating OfficerMENLO PARK, Calif., October 16, 2023--Manmeet Soni joins Summit as Chief Operating Officer. Dave Gancarz, Urte Gayko, Fong Clow, and Allen Yang have been elevated to new leadership roles. |